

## GenSight Biologics to participate in multiple upcoming investor conferences

**Paris, France, October 9, 2018, 7.30 am CEST** – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that members of its management team will participate in the following upcoming investor conferences:

### **Chardan 2<sup>nd</sup> Annual Genetic Medicines Conference**

**October 9, 2018 – New York (NY, USA)**

Thomas Gidoïn, Chief Financial Officer, and Barrett Katz, MD, Chief Medical Officer, will present on October 9, 2018, at 1:00 pm ET, at the Westin New York Grand Central Hotel in New York, NY, USA, and host investor meetings.

### **Salon Actionaria 2018**

**November 22-23, 2018 – Paris (France)**

Thomas Gidoïn, Chief Financial Officer, and members of the management team will attend the event and meet with retail investors on November 22-23 at the Palais des Congrès in Paris, France.

Bernard Gilly, Co-founder and Chief Executive Officer, will present at the “*Face aux dirigeants*” showcase on November 22, at 3:35 pm CET, and at the “*Biotech & Medtech*” showcase on November 22, at 5:15 pm CET.

### **Contacts**

#### **GenSight Biologics**

Thomas Gidoïn  
Chief Financial Officer  
[tgidoïn@gensight-biologics.com](mailto:tgidoïn@gensight-biologics.com)  
+33 (0)1 76 21 72 20

#### **RooneyPartners**

Media Relations  
Marion Janic  
[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)  
+1-212-223-4017

#### **The Trout Group**

US Investor Relations  
Chad Rubin  
[crubin@troutgroup.com](mailto:crubin@troutgroup.com)  
+1-646-378-2947

#### **James Palmer**

Europe Investor Relations  
[j.palmer@orpheonfinance.com](mailto:j.palmer@orpheonfinance.com)  
+33 7 60 92 77 74

### **About GenSight Biologics**

GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.